CAPTOPRIL AND HYDROCHLOROTHIAZIDE tablet United States - English - NLM (National Library of Medicine)

captopril and hydrochlorothiazide tablet

mylan pharmaceuticals inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - captopril 25 mg - captopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. the blood pressure lowering effects of captopril and thiazides are approximately additive. this fixed combination drug may be used as initial therapy or substituted for previously titrated doses of the individual components. when captopril and hydrochlorothiazide are given together it may not be necessary to administer captopril in divided doses to attain blood pressure control at trough (before the next dose). also, with such a combination, a daily dose of 15 mg of hydrochlorothiazide may be adequate. treatment may, therefore, be initiated with captopril and hydrochlorothiazide tablets 25 mg/15 mg once daily. subsequent titration should be with additional doses of the components (captopril, hydrochlorothiazide) as single agents or as captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg, or 50 mg/25 mg (see dosage and administration). in using captopril and hydrochlorothiazide, consideration should be give

METOPROLOL SUCCINATE tablet, extended release United States - English - NLM (National Library of Medicine)

metoprolol succinate tablet, extended release

bluepoint laboratories - metoprolol succinate (unii: th25pd4ccb) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic

METOPROLOL SUCCINATE tablet, extended release United States - English - NLM (National Library of Medicine)

metoprolol succinate tablet, extended release

cambridge therapeutics technologies, llc - metoprolol succinate (unii: th25pd4ccb) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic

METOPROLOL TARTRATE tablet, film coated United States - English - NLM (National Library of Medicine)

metoprolol tartrate tablet, film coated

actavis pharma, inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 50 mg - metoprolol tartrate tablets, usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. metoprolol tartrate tablets, usp are indicated in the long-term treatment of angina pectoris. metoprolol tartrate tablets, usp are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see dosage and administration , contraindications , and warnings ). metoprolol tartrate is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings ). hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur). sick-sinus syndrome. severe peripheral arterial circulato

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE tablet United States - English - NLM (National Library of Medicine)

metoprolol tartrate and hydrochlorothiazide tablet

physicians total care, inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - metoprolol tartrate 50 mg - metoprolol tartrate and hydrochlorothiazide tablets are indicated for the management of hypertension. this fixed-combination drug is not indicated for initial therapy of hypertension. if the fixed combination represents the dose titrated to the individual patient's needs, therapy with the fixed combination may be more convenient than with the separate components. metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings). hypersensitivity to metoprolol tartrate and related derivatives, or to any of the excipients; hypersensitivity to other beta-blockers (cross sensitivity between beta-blockers can occur). sick-sinus syndrome. severe peripheral arterial circulatory disorders. hydrochlorothiazide is contraindicated in patients with anuria or hypersensitivity to this or other sulfonamide-derived drugs (see warnings).

METOPROLOL TARTRATE- metoprolol tartrate tablet, film coated United States - English - NLM (National Library of Medicine)

metoprolol tartrate- metoprolol tartrate tablet, film coated

preferred pharmaceuticals inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 100 mg - metoprolol tartrate tablets, usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. metoprolol tartrate tablets, usp are indicated in the long-term treatment of angina pectoris. metoprolol tartrate tablets, usp are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. oral metoprolol tartrate tablets, usp therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event (see dosage and administration, contraindications , and warnings ). metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings ). hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hyperse

METOPROLOL TARTRATE tablet, film coated United States - English - NLM (National Library of Medicine)

metoprolol tartrate tablet, film coated

nucare pharmaceuticals, inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - metoprolol tartrate tablets, usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. metoprolol tartrate tablets, usp are indicated in the long-term treatment of angina pectoris. metoprolol tartrate tablets, usp are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. oral metoprolol tartrate tablets, usp therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event (see dosage and administration ,  contraindications and warnings ). metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings ). hypersensitivity

METOPROLOL- metoprolol tartrate injection United States - English - NLM (National Library of Medicine)

metoprolol- metoprolol tartrate injection

baxter healthcare corporation - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 5 mg in 5 ml - metoprolol tartrate injection is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy. hypersensitivity to metoprolol tartrate injection and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur). metoprolol tartrate injection is contraindicated in patients with a heart rate <45 beats/min; second- and third-degree heart block (unless a functioning pacemaker is present); significant first-degree heart block (p-r interval ≥0.24 sec); systolic blood pressure <100 mmhg; or decompensated cardiac failure. risk summary available data from published observational studies have not demonstrated an association of adverse developmental outcomes with maternal use of metoprolol during pregnancy (see data). untreated hypertension and heart failure during pregnancy can lead to a

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE - metoprolol tartrate and hydrochlorothiazide tablet United States - English - NLM (National Library of Medicine)

metoprolol tartrate and hydrochlorothiazide - metoprolol tartrate and hydrochlorothiazide tablet

trigen laboratories, llc - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - metoprolol tartrate 50 mg - metoprolol tartrate and hydrochlorothiazide tablets are indicated for the management of hypertension this fixed-combination drug is not indicated for initial therapy of hypertension. if the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. metoprolol metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings). hypersensitivity to metoprolol tartrate and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur). sick-sinus syndrome. severe peripheral arterial circulatory disorders. hydrochlorothiazide hydrochlorothiazide is contraindicated in patients with anuria or hypersensitivity to this or other sulfonamide-derived drugs (see warnings).

METOPROLOL TARTRATE tablet, film coated United States - English - NLM (National Library of Medicine)

metoprolol tartrate tablet, film coated

rising pharma holdings, inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic